Genotyping Direct qPCR Mixes

Direct SNP Genotyping from Crude Samples: No Extraction Required

Why Direct Genotyping Matters

The traditional workflow bottleneck:

Conventional SNP genotyping requires DNA extraction before qPCR, adding time, cost, and risk of sample loss or degradation. For labs running high-throughput testing or working with challenging sample types like FFPE tissue, this becomes a critical limitation.

The direct workflow advantage:

Meridian's mixes enable SNP detection directly from crude samples. Add your sample, run your assay. No extraction kits, no purification steps, no additional plastics or labour.

What Makes These Mixes Different?

This is the ONLY genotyping mix that's simultaneously:

Glycerol-free – Lyo-compatible for ambient-temperature stability and automation-friendly workflows
Inhibitor-tolerant – Validated on crude samples with anticoagulants, stool matrix, urine, and FFPE lysis buffer
High-concentration – Enables flexible assay optimization and smaller reaction volumes for cost savings
Validated on real clinical samples – Not just purified DNA: tested directly with human blood, stool, urine, and crude FFPE tumour tissue

Result: Tighter fluorescence clusters and clearer allele discrimination than KAPA or TaqPath mixes, even with challenging samples.

Choose Your Application

For FFPE Tumour Tissue

The challenge: Formalin fixation causes DNA cross-linking and fragmentation. Traditional workflows require time-consuming extraction with poor success rates.

The solution: Direct detection from crude FFPE lysate. Validated on lung tumour tissue for KIT, PDGFRA, and ATM mutations. Superior DNA yield vs. competing extraction buffers. Ideal for oncology diagnostics and pharmacogenomics.

For Whole Blood

Direct SNP detection from blood with anticoagulants. No DNA prep required. Applications: pharmacogenomics, cardiovascular risk screening, hereditary disease testing.

For Stool Samples

Handles PCR inhibitors naturally present in stool matrix. Direct detection for AMR monitoring, microbiome genotyping, and infectious disease diagnostics.

For Urine Samples

Direct SNP genotyping from urine for non-invasive testing. Applications: bladder cancer monitoring, infectious disease, forensics.

Technical Performance

Product Highlights:

Ultra-sensitive detection down to less than 1 copy
Suitable for crude samples as blood, urine, stool or FFPE tissue
Tight fluorescence clusters with clear allele discrimination, perfect for difficult SNPs
Can be used as a liquid or lyophilized, ideal for high throughput or POC testing

Applications & Markets

Key Applications:

Precision medicine & pharmacogenomics – Tailor drug selection based on CYP2C19, CYP2D6, TPMT variants
Clinical diagnostics – Early identification of disease risk (BRCA1/2, cardiovascular markers)
Oncology – Tumour genotyping from FFPE tissue without extraction bottlenecks
Infectious disease & AMR – Track antimicrobial resistance mutations
Forensics & agriculture – Direct genotyping for identity testing and breeding programs

Why BioCat for Genotyping Workflows

Direct genotyping represents a workflow shift, not just a reagent swap. Our team provides:

Application-specific protocol optimization for FFPE, blood, stool, and urine
Troubleshooting support for inhibitor-rich or challenging sample types
Comparative data vs. incumbent solutions (KAPA, TaqPath) to support method validation